Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Determined maximum tolerated dose in Phase 1 monotherapy study of NUV-868; Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing Received U.S. Food and Drug...
Source: marketscreener.com